FluoroPharma Medical Adds Atinsky to Board

Lawrence Atinsky, a partner at venture firm Ascent Biomedical Ventures, has joined the board of directors of FluoroPharma Medical, the company announced Friday. Before joining Ascent Biomedical, Atinsky was an attorney at Skadden Arps where he specialized in mergers and acquisitions. FluoroPharma is focused on development of proprietary PET imaging products to evaluate cardiac disease. The company is based in Boston, and traded on the over-the-counter Bulletin Board.

FluoroPharma Medical (OTCBB:FPMI) is pleased to announce that Lawrence Atinsky has been appointed to the Board of Directors of FluoroPharma effective January 3rd, 2012. Mr. Atinsky is currently a partner at Ascent Biomedical Ventures (ABV), a leading venture capital firm that focuses on investing in seed and early-stage biomedical technology companies developing medical devices, biopharmaceuticals, healthcare services, and information technology. Over the past ten years, Mr. Atinsky has worked closely with the management teams of a wide range of biotechnology companies helping them execute strategic growth plans. Prior to joining ABV, Mr. Atinsky was an attorney at Skadden Arps where he specialized in mergers and acquisitions. “I am delighted to welcome Lawrence to the FluoroPharma Board. His legal background, along with his extensive biotech business experience, brings invaluable knowledge and will complement the considerable expertise of the Board,” commented Thijs Spoor, FluoroPharma’s President, and Chief Executive Officer.

About FluoroPharma Medical
FluoroPharma is a biopharmaceutical company engaged in the discovery and development of proprietary PET imaging products to evaluate cardiac disease at the cellular and molecular levels. The Company has licensed technology form the Massachusetts General Hospital in Boston.

The Company’s goal is to enable personalized medicine through advanced imaging products that will help the medical community diagnose disease more accurately at the earliest stages, leading to more effective treatment, management and better patient outcomes.

The Company’s initial focus is the development of breakthrough positron emission tomography (PET) imaging agents for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). FluoroPharma is advancing two products in clinical trials for assessment of acute and chronic forms of coronary disease. These first in class agents have been designed to rapidly target myocardial cells. Other products in development include agents for detection of inflamed atherosclerotic plaque in peripheral arteries, agents with the potential to image Alzheimer’s disease and agents that could potentially be used for imaging specific cancers.

Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward looking statements in this news release include statements regarding FluoroPharma’s research and development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as significant fluctuations in expenses associated with clinical trials, failure to secure additional financing, the inability to complete regulatory filings with the Food and Drug Administration, the introduction of competing products, or management’s ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in FluoroPharma’s filings with the United States Securities and Exchange Commission. FluoroPharma undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.